Chairman of the Board of Directors and Chief Executive Officer of GENFIT, Co-founder
Jean-François Mouney co-founded GENFIT in 1999 after having been actively involved in the incubation of the Company from 1997. Prior to this, he had created, managed and developed several companies specializing in high-performance materials, particularly in the aeronautical industry, since 1979. In 1992, he founded M&M, a consultancy firm specializing in health economics. He was responsible for carrying out a feasibility study for an economic development agency within the field of health and biology in the Nord-Pas-de-Calais region of France and was appointed Chief Executive Officer of this agency since its launch in 1995.
Over a hundred companies have been created as part of this venture, making Eurasanté one of the top European bioincubators and clusters. As Chairman of the Executive Board of GENFIT, he received, in 2003, the Entrepreneur of the Year award, which is organized internationally by Ernst & Young, in the New Technology category. He also received this award in 2004. Jean-François Mouney is also Deputy Chairman of the “Nutrition, Health and Longevity” research hub and is Advisor to the Banque de France since 2008.
Jean-François Mouney is a graduate of the ESCP-Europe Business School, and holds a Master Degree in Economics from the University of Lille.
Hugues Bienaymé, PhD
General Manager and Chief Scientific Officer at ORPHELIA Pharma.
Mr. Hugues Bienaymé, PhD has more than 25 years of experience in pharmaceutical industry both in pharma (Aventis, Pierre Fabre) and in biotech companies (Chrysalon, Urogene). He is the founder of ORPHELIA Pharma (previously TargeOn), a company focussed in the development of paediatrics medicines in neurology and oncology. Prior to ORPHELIA Pharma, M. Bienaymé was Managing Director and CSO of Pierre Fabre Urology, a subsidiary of Pierre Fabre Medicament dedicated to the development of drugs in the urology space. Mr. Bienaymé also founded and served as President of Chrysalon, a combinatorial and medicinal chemistry biotech company, which merged with the onco-urology company Urogene in 2004. He spent 10 years with Rhône-Poulenc (now sanofi-aventis), heading research groups in combinatorial and medicinal chemistry. He was awarded several distinctions, including the Industrial Prize of the French National Chemical Society (2003); the Aventis-Institut de France Foundation prize (2001); the French Ministry of Education and Research start-up company prize (2000 & 2001); the Prize of the Organic Chemistry Division (French National Chemical Society, 1998). He is Author or Co-author of 39 peer-reviewed articles and 18 patents.
Prof. Benoit Deprez
Founder of APTEEUS
Benoit studied Industrial Pharmacy Lille from 1985 to 1991 and received his PhD in combinatorial chemistry. With Andre Tartar he created the automated parallel synthesis laboratory at the Institut Pasteur de Lille, becoming later the department of drug discovery of Cerep (30 employees). To finance its development, Cerep goes public in 1998, having signed a major collaboration agreement with Sanofi. In late 1999, Benoit and part of his team join the young company Devgen to launch drug discovery activities. Benoit Deprez has managed several multi-annual collaborations with pharmaceutical companies and biotechs. In 2006, he founded a drug discovery lab at INSERM. The laboratory has run into several collaborations with industries and licensed several patents. Benoit was a member of the Strategic Committee of Inserm-transfer for 5 years. He is a member of the National Academy of Pharmacy and advisor to several venture funds. He is author of 80 international publications and 12 patent families. In March 2014, he obtained an MBA from EDHEC.